Early COVID-19 Vaccine Initiation and Completion Among Cancer Survivors and Barriers to Vaccine Completion: Implications for Future COVID-19 Vaccination Uptake Rates

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2024-11-25 DOI:10.1002/cam4.70428

Nikta Saeedi, Angel Arizpe, Katelyn J. Queen, Jennifer Tsui, Sue Kim, Brian Z. Huang, Albert J. Farias

{"title":"Early COVID-19 Vaccine Initiation and Completion Among Cancer Survivors and Barriers to Vaccine Completion: Implications for Future COVID-19 Vaccination Uptake Rates","authors":"Nikta Saeedi, Angel Arizpe, Katelyn J. Queen, Jennifer Tsui, Sue Kim, Brian Z. Huang, Albert J. Farias","doi":"10.1002/cam4.70428","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>Cancer survivors are considered by public health officials as a high-risk group in the United States for severe complications from COVID-19. We aimed to characterize patterns of early uptake of the COVID-19 vaccine among cancer survivors and to determine modifiable barriers to vaccine completion that can be addressed to ensure future booster adherence.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Cross-sectional data of vaccine uptake by summer 2021 was extracted from adult cancer survivors enrolled in the “All of Us” research program. Vaccine completion was determined based on receiving at least two doses. We assessed sociodemographic factors, socioeconomic barriers (education, income, health insurance status, housing, and employment status), and COVID-19 vaccine uptake by Summer 2021, employing multivariable ordinal logistic regression for those who were unvaccinated, had initiated vaccine uptake, and had completed COVID-19 vaccination.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of the 514 cancer survivors in the sample, 73.7% were fully vaccinated by summer 2021. Those who received no vaccine doses showed higher proportions of SES barriers, medical distrust, and perceived lack of need barriers. Race (non-Hispanic White vs. other) was not statistically significantly associated with vaccine uptake (OR (95% CI) = 0.94 (0.51, 1.70)), while for every additional SES barrier, there was a 40% decrease (OR (95% CI) = 0.60 (0.48, 0.75)) in the odds of receiving more COVID-19 vaccine doses. Higher medical distrust and perceived lack of need were associated with 56% (OR = 0.44, 95% CI: 0.32–0.59) and 39% (OR = 0.61, 95% CI: 0.43–0.87) lower odds, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Racial/ethnic disparities in vaccine uptake may be explained by SES barriers. Addressing SES disparities and fostering medical trust may enhance future COVID-19 vaccination uptake rates for this high-risk group.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70428","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70428","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Cancer survivors are considered by public health officials as a high-risk group in the United States for severe complications from COVID-19. We aimed to characterize patterns of early uptake of the COVID-19 vaccine among cancer survivors and to determine modifiable barriers to vaccine completion that can be addressed to ensure future booster adherence.

Methods

Cross-sectional data of vaccine uptake by summer 2021 was extracted from adult cancer survivors enrolled in the “All of Us” research program. Vaccine completion was determined based on receiving at least two doses. We assessed sociodemographic factors, socioeconomic barriers (education, income, health insurance status, housing, and employment status), and COVID-19 vaccine uptake by Summer 2021, employing multivariable ordinal logistic regression for those who were unvaccinated, had initiated vaccine uptake, and had completed COVID-19 vaccination.

Results

Of the 514 cancer survivors in the sample, 73.7% were fully vaccinated by summer 2021. Those who received no vaccine doses showed higher proportions of SES barriers, medical distrust, and perceived lack of need barriers. Race (non-Hispanic White vs. other) was not statistically significantly associated with vaccine uptake (OR (95% CI) = 0.94 (0.51, 1.70)), while for every additional SES barrier, there was a 40% decrease (OR (95% CI) = 0.60 (0.48, 0.75)) in the odds of receiving more COVID-19 vaccine doses. Higher medical distrust and perceived lack of need were associated with 56% (OR = 0.44, 95% CI: 0.32–0.59) and 39% (OR = 0.61, 95% CI: 0.43–0.87) lower odds, respectively.

Conclusion

Racial/ethnic disparities in vaccine uptake may be explained by SES barriers. Addressing SES disparities and fostering medical trust may enhance future COVID-19 vaccination uptake rates for this high-risk group.

查看原文本刊更多论文

癌症幸存者早期接种 COVID-19 疫苗和完成接种的障碍：对未来 COVID-19 疫苗接种率的影响

目的在美国，癌症幸存者被公共卫生官员视为 COVID-19 严重并发症的高危人群。我们的目的是描述癌症幸存者早期接种 COVID-19 疫苗的模式，并确定完成疫苗接种的可调节障碍，以确保未来加强接种的依从性。方法从参加 "我们大家 "研究计划的成年癌症幸存者中提取了 2021 年夏季疫苗接种情况的横断面数据。疫苗接种完成度根据至少接种两剂疫苗来确定。我们评估了社会人口学因素、社会经济障碍（教育、收入、医疗保险状况、住房和就业状况）以及到 2021 年夏季的 COVID-19 疫苗接种情况，对未接种、已开始接种和已完成 COVID-19 疫苗接种的人群进行了多变量序数逻辑回归。结果在样本中的 514 名癌症幸存者中，73.7% 的人在 2021 年夏季之前完全接种了疫苗。未接种疫苗的幸存者中，有较高比例的人存在社会经济地位障碍、对医疗的不信任以及认为没有必要接种疫苗的障碍。种族（非西班牙裔白人与其他种族）与疫苗接种率无显著统计学关联（OR (95% CI) = 0.94 (0.51, 1.70)），而每增加一个社会经济障碍，接种更多剂量 COVID-19 疫苗的几率就会降低 40% (OR (95% CI) = 0.60 (0.48, 0.75))。较高的医疗不信任度和缺乏需求感分别导致接种几率降低 56%（OR = 0.44，95% CI：0.32-0.59）和 39%（OR = 0.61，95% CI：0.43-0.87）。结论疫苗接种率的种族/民族差异可能是由社会经济条件障碍造成的。解决社会经济地位的差异和促进医疗信任可能会提高这一高风险群体未来的 COVID-19 疫苗接种率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.